Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635434 · ClinicalTrials.gov registry record · Early Phase 1
An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients
A Early Phase 1 study of Pain and Pediatric Cancer, sponsored by ALTality.
- Active
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06635434: Active Early Phase 1 study of Pain and Pediatric Cancer, sponsored by ALTality.
NCT06635434 is a Early Phase 1 study of Pain and Pediatric Cancer that is active but no longer recruiting, run by ALTality. The registered enrollment target is 16 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06635434, a Early Phase 1 study of Pain and Pediatric Cancer, is active but no longer recruiting, sponsored by ALTality.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
In this SBIR, ALTality, Inc. ("SpellBound") will assess the feasibility of a dual English/Spanish language augmented reality(AR)-enabled tool for assessing inpatient postoperative pain/nausea/vomiting in Hispanic/Latino children and adolescents with cancer in collaboration with bilingual Spanish-speaking anesthesiologists at the MD Anderson Cancer Center. If successful, the AR app will be an immediately implementable and commercially viable method of providing Hispanic/Latino pediatric cancer patients with limited English proficiency an adjunctive tool to overcome infrastructural barriers to receiving translation services in acute care settings that put them at higher risk of under and/or overtreatment of pain by prescription opioids and future prescription opioid dependency and misuse, at no cost to them or their families.
Primary Outcome
Feasibility measured as activation/usage of the app recorded by the device ID for each patient
Conditions Studied
Interventions
- DEVICE AR Pain assessment
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-02-05 |
| Est. Completion | 2024-11-30 |
| Phase | Early Phase 1 |
What the registry record for NCT06635434 still lists
NCT06635434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which AR Pain assessment is the first listed.
NCT06635434 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06635434 about?
NCT06635434 is a clinical study titled "An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients". In this SBIR, ALTality, Inc. ("SpellBound") will assess the feasibility of a dual English/Spanish language augmented reality(AR)-enabled tool for assessing inpatient postoperative pain/nausea/vomiting in Hispanic/Latino children and adolescents with cancer in collaboration with bilingual Spanish-spe...
What is the current status of trial NCT06635434?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2023-02-05. Estimated completion is 2024-11-30.
What conditions does trial NCT06635434 study?
This clinical trial studies the following conditions: Pain, Pediatric Cancer.
What interventions are being tested in trial NCT06635434?
The interventions under investigation include: AR Pain assessment (DEVICE).
Who is sponsoring clinical trial NCT06635434?
This trial is sponsored by ALTality, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635434 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06635434's enrollment target sits among peer trials
16 351st of 374 higher than 24 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination
RECRUITING · Early Phase 1
-
The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults
RECRUITING · Early Phase 1
-
Effects of Dronabinol in Opioid Maintained Patients
RECRUITING · Early Phase 1
-
Remimazolam NeuroImaging
RECRUITING · Early Phase 1
-
Nitrous Oxide Neuroimaging
RECRUITING · Early Phase 1
-
Ketamine and Propofol NeuroImaging
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI